Sickle cell protection from malaria

Sandro Eridani, Sandro Eridani

Abstract

A linkage between presence of Sickle Haemoglobin (HbS) and protection from malaria infection and clinical manifestations in certain areas was suspected from early observations and progressively elucidated by more recent studies. Research has confirmed the abovementioned connection, but also clarified how such protection may be abolished by coexistence of sickle cell trait (HbS trait) and alpha thalassemia, which may explain the relatively low incidence of HbS trait in the Mediterranean. The mechanisms of such protective effect are now being investigated: factors of genetic, molecular and immunological nature are prominent. As for genetic factors attention is given to the role of the red blood cell (RBC) membrane complement regulatory proteins as polymorphisms of these components seem to be associated with resistance to severe malaria; genetic ligands like the Duffy group blood antigen, necessary for erythrocytic invasion, and human protein CD36, a major receptor for P. falciparum-infected RBC's, are also under scrutiny: attention is focused also on plasmodium erythrocyte-binding antigens, which bind to RBC surface components. Genome-wide linkage and association studies are now carried out too, in order to identify genes associated with malaria resistance. Only a minor role is attributed to intravascular sickling, phagocytosis and haemolysis, while specific molecular mechanisms are the object of intensive research: among these a decisive role is played by a biochemical sequence, involving activation of haeme oxygenase (HMO-1), whose effect appears mediated by carbon monoxide (CO). A central role in protection from malaria is also played by immunological factors, which may stimulate antibody production to plasmodium antigens in the early years of life; the role of agents like pathogenic CD8 T-cells has been suggested while the effects of molecular actions on the immunity mechanism are presently investigated. It thus appears that protection from malaria can be explained by interaction of different factors: the elucidation of such mechanisms may prove valuable for the prevention and treatment strategy of a disease which still affects large parts of the world.

Keywords: CD8-Tcells.; haeme-oxygenase; haemoglobin S; immunity acquisition; protection from malaria; sickle cell trait.

Conflict of interest statement

Conflict of interest: the authors report no conflicts of interest.

References

    1. Valentine WN, Neil JV. Hematologic and genetic studies on the transmission of Thalassemia minor (Mediterranean anemia) Arch Int Med. 1944;74:185–196.
    1. Haldane JBS. The rate of mutation of human genes. Hereditas. 1949;35:267–73.
    1. Siniscalco M, Bernini L, Filippi G, et al. Population genetics of haemoglobin variants, thalassaemia and glucose-6-phosphate dehydrogenase deficiency, with particular reference to the malaria hypothesis. Bull World Health Organ. 1966;34:379–93.
    1. Luzzatto L, Nwachuku-Jarrett ES, Reddy S. Increased sickling of parasitised erythrocytes as mechanism of resistance against malaria in the sickle-cell trait. Lancet. 1970;1:319–21.
    1. Ruwende C, Hill A. Glucose-6-phosphate dehydrogenase deficiency and malaria. J Mol Med. 1998;76:581–8.
    1. Allen SJ, O'Donnell A, Alexander ND, et al. Prevention of cerebral malaria in children in Papua New Guinea by SAO band 3. Am J Trop Med Hyg. 1999;60:1056–60.
    1. Modiano D, Luoni G, Sirima BS, et al. Haemoglobin C protects against clinical falciparum malaria. Nature. 2001;414:305–8.
    1. Kodjo A, Min-Oo G, Serghides L, et al. Pyruvate kinase deficiency and malaria. New Engl J Med. 2008;358:1805–10.
    1. Clegg JB, Weatherall DJ. Thalassemia and malaria: new insights into an old problem. Proc Assoc Am Physicians. 1999;111:278–82.
    1. Beet EA. Sickle cell disease in northern Rhodesia. East Afr Med J. 1947;24:212–22.
    1. Allison AC. The distribution of the sickle-cell trait in East Africa and elsewhere, and its apparent relationship to the incidence of subtertian malaria. Trans R Soc Trop Med Hyg. 1954;48:312–8.
    1. Allison A.C. Polymorphism and natural selection in human populations. Cold Spring Harb Symp Quant Biol. 1964;29:137–49.
    1. May J, Evans JA, Timmann C, et al. Hemoglobin variants and disease manifestations in severe falciparum malaria. JAMA. 2007;297:2220–6.
    1. Williams TN. Human red blood cell polymorphisms and malaria. Curr Opin Microbiol. 2006;9:388–94.
    1. Barrai I, Schiliro G, Beretta M. Population structure of Sicily: beta-thalassemia and HbS. Hum Genet. 1987;75:1–3.
    1. Penman BS, Pybus OG, Weatherall DG, Gupta S. Epistatic interactions between genetic disorders of hemoglobin can explain why the sickle-cell gene is uncommon in the Mediterranean. Proc Natl Acad Sci. 2009;106:21242–6.
    1. Weatherall DJ. Genetic variation and susceptibility to infection: the red cell and malaria. Brit J Haemat. 1998;141:276–86.
    1. Bunn HF. Mechanisms of disease-pathogenesis and treatment of sickle cell disease. N Engl J Med. 1997;337:762–9.
    1. Piel FB, Patil AP, Howes RE, et al. Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis. Nat Commun. 2010;1:104–104.
    1. Eaton WA, Hofrichter J. Sickle cell hemoglobin polymerization. Adv Protein Chem. 1990;40:63–279.
    1. Corbett JD, Mickols WE, Maestre MF. Effect of hemoglobin concentration on nucleation and polymer formation in sickled red blood cells. J Biol Chem. 1995;270:2708–15.
    1. Raberg L, Sim D, Read F. Disentangling genetic variation of resistance and tolerance to infectious diseases in animals. Science. 2007;318:812–14.
    1. Williams TN. Human red blood cell polymorphisms and malaria. Curr Opin Microbiol. 2006;9:388–94.
    1. Cockburn IA, Mackinnon MJ, O'Donnell A, et al. A human complement receptor 1 polymorphism that reduces Plasmodium falciparum rosetting confers protection against severe malaria. Proc Natl Acad Sci USA. 2004;101:272–7.
    1. Thathy V, Moulds JM, Guyah B, Otieno W. Stoute JA: Complement receptor 1 polymorphisms associated with resistance to severe malaria in Kenya. Malar J. 2005;4:54–54.
    1. Mayor A, Bir N, Sawhney R, et al. Receptor-binding residues lie in central regions of Duffy-binding-like domains involved in red cell invasion and cytoadherence by malaria parasites. Blood. 2005;105:2557–63.
    1. Booth PB, McLoughlin K. The Gerbich blood group system, especially in Melanesians. Vox Sang. 1972;22:73–84.
    1. Thompson JK, Triglia T, Reed MB, Cowman AF. A novel ligand from Plasmodium falciparum that binds to a sialic acid containing receptor on the surface of human erythrocytes. Mol Microbiol. 2001;41:47–58.
    1. Walker PS, Reid ME. The Gerbich blood group system: a review. Immunohematology. 2010;26:60–5.
    1. Baruch DI, Ma XC, Pasloske B, et al. CD36 peptides that block cytoadherence define the CD36 binding region for Plasmodium falciparum-infected erythrocytes. Blood. 1999;94:2121–212.
    1. Urban BC, Ferguson DJ, Pain A, et al. Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells. Nature. 1999;400:73–7.
    1. Aitman TJ, Cooper LD, Norsworthy PJ, et al. Malaria susceptibility and CD36 mutation. Nature. 2000;405:1015–6.
    1. Fry AE, Ghansa A, Small KS, et al. Positive selection of a CD36 nonsense variant in sub-Saharan Africa, but no association with severe malaria phenotypes. Hum Mol Genet. 2009;18:2683–92.
    1. Adams JH, Sim BK, Dolan SA, et al. A family of erythrocyte binding proteins of malaria parasites. Proc Natl Acad Sci. 1992;89:7085–9.
    1. Duraisingh MT, Maier AG, Triglia T, Cowman AF. Erythrocyte-binding antigen 175 mediates invasion in Plasmodium falciparum utilizing sialic acid-dependent and -independent pathways. Proc Natl Acad Sci USA. 2003;100:4796–801.
    1. Gilberger TW, Thompson JK, Triglia T, et al. A novel erythrocyte binding antigen- 175 paralogue from Plasmodium falciparum defines a new trypsin-resistant receptor on human erythrocytes. J Biol Chem. 2003;278:14480–6.
    1. Milet J, Nuel G, Watier L, et al. Genome Wide Linkage Study, Using a 250K SNP Map, of Plasmodium falciparum Infection and Mild Malaria Attack in a Senegalese Population. PLoS ONE. 2010;5:11–11.
    1. Sambo MR, Trovoada MJ, Benchimol C, et al. Transforming Growth Factor Beta 2 and Heme Oxygenase 1 Genes Are Risk Factors for the Cerebral Malaria Syndrome in Angolan Children. PLoS ONE. 2010;5:e11141.
    1. Luzzatto L, Nwachuku-Jarrett ES, Reddy S. Increased sickling of parasitised erythrocytes as mechanism of resistance against malaria in the sickle-cell trait. Lancet. 1970;1:319–21.
    1. Edelstein SJ, Crepeau RH. Oblique alignment of hemoglobin-S fibers in sickled cells. J Mol Biol. 1979;134:851–5.
    1. Eaton WA, Hofrichter J. Hemoglobin S gelation and sickle cell disease. Blood. 1987;70:1245–66.
    1. Christoph GW, Hofrichter J, Eaton WA. Understanding the Shape of Sickled Red Cells. Biophys J. 2005;88:1371–6.
    1. Eridani S, Mosca A. Fetal hemoglobin reactivation and cell engineering in the treatment of sickle cell anemia. J. Blood Medicine. 2011;2:23–30.
    1. Hebbel P, Morgan WT, Eaton JW, Hedlund BO. Accelerated autoxidation and heme loss due to instability of sickle haemoglobin. Proc Natl Acad Sci. 1988;85:237–41.
    1. Tenhunen R, Marver HS, Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci. 1968;61:748–748.
    1. Alam J, Stewart D, Touchard C, et al. Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J Biol Chem. 1999;274:26071–8.
    1. Marsh K, Forster D, Waruiru C, et al. Indicators of life-threatening malaria in African children. N Engl J Med. 1995;332:1399–1404.
    1. Alam J, Cook JL. Heme oxygenase-1: a multi-faceted triple-threat molecule. Am J Resp Cell Mol Biol. 2007;36:166–74.
    1. Belcher JD, Mahaseth H, Welch TE, Otterbein LE, Hebbel RP, Vercellotti GM. Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. J Clin Invest. 2006;116:808–16.
    1. Ferreira A, Balla J, Jeney V, Soares MP. A central role for free heme in the pathogenesis of severe malaria: the missing link? J Mol Med. 2008;86:1097–111.
    1. Balla G, Jacob HS, Balla J, et al. Ferritin: a cytoprotective antioxidant strategem of endothelium. J Biol Chem. 1992;267:18148–53.
    1. Ayn K, Turrini F, Piga A, Arese P. Enhanced phagocytosis of ring-parasitized mutant erythrocytes: a common mechanism that may explain protection against falciparum malaria in sickle trait and beta-thalassemia trait. Blood. 2004;104:3364–71.
    1. May JA, Evans C, Timmann C, et al. Hemoglobin variants and disease manifestations in severe falciparum malaria. JAMA. 2007;297:2220–6.
    1. Ferreira A, Marguti I, Bechmann I, et al. Sickle Hemoglobin Confers Tolerance to Plasmodium Infection. Cell. 2011;145:398–409.
    1. Marsh K, Otoo L, Hayes RJ, et al. Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection. Trans R Soc Trop Med Hyg. 1989;83:293–303.
    1. Cabrera G, Cot M, Migot-Nabias F, et al. The sickle cell trait is associated with enhanced immunoglobulin G antibody responses to Plasmodium falciparum variant surface antigens. J Infect Dis. 2005;191:1631–8.
    1. Ferreira A, Balla J, Jeney V, et al. A central role for free heme in the pathogenesis of severe malaria: the missing link? J Mol Med. 2008;86:1097–111.
    1. Williams TN, Mwangi TW, Roberts DJ, et al. An immune basis for malaria protection by the sickle cell trait. PLoS Med. 2005;2:e128–e128.
    1. Read AF, Graham AL, Råberg L. Animal defenses against infectious agents: is damage control more important than pathogen control. PLoS Biol. 2008;6:e1000004
    1. Seixas E, Gozzelino R, Chora A, et al. Heme oxygenase-1 affords protection against noncerebral forms of severe malaria. Proc Natl Acad Sci. 2009;106:15837–42.
    1. Mackinnon MJ, Mwangi TW, Snow RW, et al. Heritability of Malaria in Africa. PLoS Med. 2005;2:e340–e340.
    1. Hood AT, Fabry ME, Costantini F, et al. Protection from lethal malaria in transgenic mice expressing sickle hemoglobin. Blood. 1996;87:1600–3.
    1. Schneider DS, Ayres JS. Two ways to survive infection: what resistance and tolerance can teach us about treating infectious diseases. Nat Re. Immunol. 2008;8:889–95.
    1. Crompton PD, Traore B, Kayentao K, et al. Sickle Cell Trait is Associated with a Delayed Onset of Malaria: Implications for Time to Event Analysis in Clinical Studies of Malaria. J Infect Dis. 2008;198:1265–75.
    1. Pamplona A, Ferreira A, Balla, et al. Heme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria. Nat Med. 2007;13:703–10.
    1. D'Ombrain MC, Robinson LJ, Stanisic DI, et al. Association of early interferon-γ production with immunity to clinical malaria: a longitudinal study among Papua New Guinea children. Clin Infect Dis. 2008;47:1380–7.
    1. Sharma S, DeOliveira R, Kalantari P, et al. Innate Immune Recognition of an AT-Rich Stem-Loop DNA Motif in the Plasmodium falciparum Genome. Immunity. 2011;35:194–207.
    1. Schuldt K, Kretz CC, Timmann C, et al. A - 436C>A polymorphism in the human FAS gene promoter associated with severe childhood malaria. 2011;7:e1002066
    1. Crompton PD, Pierce SK, Miller LH. Advances and challenges in malaria vaccine development. J Clin Invest. 2010;120:4168–78.
    1. Thompson FM, Porter DW, Okitsu SL, et al. Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS One. 2008;3:e1493–e1493.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren